Carlsmed

Carlsmed Equity

The The Equity of Carlsmed (CARL) as of Oct 21, 2026 is 25.60 M USD. In the previous year, The Equity was -2.75 M USD — a change of -1,030.43% (higher).

Equity

25.60 MUSD

YoY

-1,030.43%

Last updated:

In 2024, Carlsmed's equity was 25.60 M USD, a -1,030.43% increase from the -2.75 M USD equity in the previous year.

The Carlsmed Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2023
-2.75 M USD
Jan 1, 2024
25.60 M USD
The Carlsmed Equity history
YEAREquityYoY
25.60 MUSD-1,030.43%
-2.75 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carlsmed Stock analysis

What does Carlsmed do? Carlsmed, Inc. generates revenue through its aprevo technology platform, which provides AI-based solutions for the surgical workflow. The platform includes pre-operative AI-enabled planning software that uses diagnostic imaging and algorithms to create personalized surgical plans and design aprevo interbody implants. Intra-operative advanced visualization tools support precision placement of these implants, while post-operative data collection offers insights to refine future planning. The company targets medical professionals and hospitals in the United States, focusing on lumbar interbody fusion procedures. Its products are sold under the aprevo brand, with the platform available in the U.S. market for surgical planning and implant design. Carlsmed's revenue streams come from the commercial sale of its aprevo technology platform, which integrates pre-operative planning, intra-operative visualization, and post-operative data analytics. The platform is specifically designed for lumbar interbody fusion procedures, addressing the needs of healthcare providers seeking to enhance surgical precision and outcomes. By leveraging AI-driven tools, Carlsmed enables personalized implant design and real-world data collection to improve surgical planning processes. The company's offerings are marketed to hospitals and surgeons in the U.S. healthcare sector, emphasizing the aprevo brand's role in digital surgical planning. The aprevo technology platform serves as Carlsmed's core product, offering a comprehensive solution for surgical workflows. Its pre-operative software utilizes standard-of-care imaging and AI algorithms to develop patient-specific plans and implant designs. Intra-operative tools provide advanced visualization for precise implant placement, while post-operative data collection informs continuous improvement of the planning process. The platform is indicated for use in lumbar interbody fusion procedures and is commercially available in the United States, targeting healthcare institutions that prioritize AI-enhanced surgical planning and outcomes. Carlsmed is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Carlsmed's Equity

Carlsmed's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Carlsmed's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Carlsmed's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Carlsmed's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Carlsmed’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Carlsmed stock

The Equity of Carlsmed is 25.60 M USD in 2024.

The Equity of Carlsmed changed from -2.75 M USD to 25.60 M USD, representing a -1,030.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Carlsmed since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Carlsmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Carlsmed

All Key Metrics — Carlsmed